Cargando…
Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma
PURPOSE: Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demo...
Autores principales: | Zhu, Zhenfeng, Xu, Litao, Zhuang, Liping, Ning, Zhouyu, Zhang, Chenyue, Yan, Xia, Lin, Junhua, Shen, Yehua, Wang, Peng, Meng, Zhiqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188073/ https://www.ncbi.nlm.nih.gov/pubmed/30349306 http://dx.doi.org/10.2147/OTT.S173275 |
Ejemplares similares
-
High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells
por: Ning, Zhouyu, et al.
Publicado: (2019) -
Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients
por: Xu, Litao, et al.
Publicado: (2017) -
Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2016) -
Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2017) -
Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway
por: Wang, Haiyong, et al.
Publicado: (2016)